Solution Manual for Genetics and Genomics for Nursing
Get accurate solutions for your textbook problems with Solution Manual for Genetics and Genomics for Nursing, your go-to guide for textbook answers.
Sofia Garcia
Contributor
5.0
32
4 months ago
Preview (16 of 360)
Sign in to access the full document!
Kenner/Lewis: Genetics and Genomics for Nursing, 1e
Chapter 1: Genetics and Genomics: Definitions and Trends
Case Study Questions
Genetic Biomarker (GB) testing is becoming more popular as the cost and relevancy of
pharmacogenomics testing becomes better known and easily applicable to clinical practice. A site
referencing required, recommended, or for information only testing is available on the FDA website
at www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. This
will assist in answering the following questions:
A registered nurse is assigned to care for three patients who are receiving medications that are
known to be associated with genetic traits or GB(s) that could alter the effect of the drug. Identify if
the GB has required, recommended, or for information only status for testing.
This activity contains 3 questions.
1. L.L. is a 52-year-old Caucasian female being treated with Herceptin for her recently diagnosed
her2/neu positive breast cancer.
Answer: Required. The breast cancer tumor must be tested for the presence of the her2/neu
receptor in order to receive Herceptin.
2. R.N. is a 62-year-old male with a new diagnosis of rheumatoid arthritis and has been
prescribed Celebrex 200mg b.i.d.
Answers: Recommended if PM status suspected. Poor metabolizers (PM) of Celebrex should have
dosage reduced by 50%. If this patient is a PM the dose should be reduced to 100mg b.i.d. and
monitored for side effects.
www.accessdata.fda.gov/drugsatfda_docs/label/2011/020998s033,021156s003lbl.pdf
3. M.G. is a 26-year-old Ethiopian new mom who delivered her first child by a caesarean section.
She was prescribed codeine 30mg p.o. and is breastfeeding her newborn.
Answers: Because of her Ethiopian ancestry, M.G. could be an Ultra-rapid metabolizer and should
receive a non-codeine analgesic.
www.accessdata.fda.gov/drugsatfda_docs/label/2012/022402s003lbl.pdf
Chapter 1: Genetics and Genomics: Definitions and Trends
Case Study Questions
Genetic Biomarker (GB) testing is becoming more popular as the cost and relevancy of
pharmacogenomics testing becomes better known and easily applicable to clinical practice. A site
referencing required, recommended, or for information only testing is available on the FDA website
at www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. This
will assist in answering the following questions:
A registered nurse is assigned to care for three patients who are receiving medications that are
known to be associated with genetic traits or GB(s) that could alter the effect of the drug. Identify if
the GB has required, recommended, or for information only status for testing.
This activity contains 3 questions.
1. L.L. is a 52-year-old Caucasian female being treated with Herceptin for her recently diagnosed
her2/neu positive breast cancer.
Answer: Required. The breast cancer tumor must be tested for the presence of the her2/neu
receptor in order to receive Herceptin.
2. R.N. is a 62-year-old male with a new diagnosis of rheumatoid arthritis and has been
prescribed Celebrex 200mg b.i.d.
Answers: Recommended if PM status suspected. Poor metabolizers (PM) of Celebrex should have
dosage reduced by 50%. If this patient is a PM the dose should be reduced to 100mg b.i.d. and
monitored for side effects.
www.accessdata.fda.gov/drugsatfda_docs/label/2011/020998s033,021156s003lbl.pdf
3. M.G. is a 26-year-old Ethiopian new mom who delivered her first child by a caesarean section.
She was prescribed codeine 30mg p.o. and is breastfeeding her newborn.
Answers: Because of her Ethiopian ancestry, M.G. could be an Ultra-rapid metabolizer and should
receive a non-codeine analgesic.
www.accessdata.fda.gov/drugsatfda_docs/label/2012/022402s003lbl.pdf
Kenner/Lewis: Genetics and Genomics for Nursing, 1e
Chapter 1: Genetics and Genomics: Definitions and Trends
Case Study Questions
Genetic Biomarker (GB) testing is becoming more popular as the cost and relevancy of
pharmacogenomics testing becomes better known and easily applicable to clinical practice. A site
referencing required, recommended, or for information only testing is available on the FDA website
at www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. This
will assist in answering the following questions:
A registered nurse is assigned to care for three patients who are receiving medications that are
known to be associated with genetic traits or GB(s) that could alter the effect of the drug. Identify if
the GB has required, recommended, or for information only status for testing.
This activity contains 3 questions.
1. L.L. is a 52-year-old Caucasian female being treated with Herceptin for her recently diagnosed
her2/neu positive breast cancer.
2. R.N. is a 62-year-old male with a new diagnosis of rheumatoid arthritis and has been
prescribed Celebrex 200mg b.i.d.
3. M.G. is a 26-year-old Ethiopian new mom who delivered her first child by a caesarean section.
She was prescribed codeine 30mg p.o. and is breastfeeding her newborn.
Chapter 1: Genetics and Genomics: Definitions and Trends
Case Study Questions
Genetic Biomarker (GB) testing is becoming more popular as the cost and relevancy of
pharmacogenomics testing becomes better known and easily applicable to clinical practice. A site
referencing required, recommended, or for information only testing is available on the FDA website
at www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. This
will assist in answering the following questions:
A registered nurse is assigned to care for three patients who are receiving medications that are
known to be associated with genetic traits or GB(s) that could alter the effect of the drug. Identify if
the GB has required, recommended, or for information only status for testing.
This activity contains 3 questions.
1. L.L. is a 52-year-old Caucasian female being treated with Herceptin for her recently diagnosed
her2/neu positive breast cancer.
2. R.N. is a 62-year-old male with a new diagnosis of rheumatoid arthritis and has been
prescribed Celebrex 200mg b.i.d.
3. M.G. is a 26-year-old Ethiopian new mom who delivered her first child by a caesarean section.
She was prescribed codeine 30mg p.o. and is breastfeeding her newborn.
Loading page 6...
Loading page 7...
Loading page 8...
Loading page 9...
Loading page 10...
Loading page 11...
Loading page 12...
Loading page 13...
Loading page 14...
Loading page 15...
Loading page 16...
13 more pages available. Scroll down to load them.
Preview Mode
Sign in to access the full document!
100%